12th July 2019, Volume 132 Number 1498

Gemma A Laws, Roslyn A Kemp

Probiotics and the microbiome In recent years there has been a surge in research investigating the human microbiome. Each individual has their own microbiota, the collection of microorganisms that colonise…

Subscriber content

The full contents of this page is only available to subscribers.

To view this content please login or subscribe

Summary

Probiotics available in New Zealand have a range of reported health benefits, and it can be difficult for consumers and healthcare professionals to compare efficacy of different products. Probiotic products contain a variety of bacterial species and strains that interact with our bodies in unique ways and provide different health benefits, and it is important to acknowledge that these strains cannot be compared unless tested in standardised way. Development of an online resource that collates and translates the scientific literature on probiotics into easy-to-understand clinically relevant information would help consumers and healthcare professionals compare probiotic products and make informed decisions.

Abstract

Research into the health benefits of probiotics has growing interest. Reported benefits of probiotic consumption range from the improvement of intestinal function to immune support. However, trials of probiotics lack the standardisation required to judge efficacy. It is important to acknowledge that probiotic products include a range of bacterial species and strains that can have varied effects. In this article, we address the importance of correctly interpreting trials of proposed probiotics. We discuss the necessity to treat probiotic bacterial strains independently, and to communicate findings consistently through both data reporting and product labelling. Finally, we propose a new approach to study the health effects of probiotics in the future.

Author Information

Gemma Laws, MSc Candidate, Department of Microbiology and Immunology, University of Otago, Dunedin; Roslyn Kemp, Associate Professor, Department of Microbiology and Immunology, University of Otago, Dunedin.

Correspondence

Roslyn Kemp, Department of Microbiology and Immunology, University of Otago, PO Box 56, Dunedin.

Correspondence Email

roslyn.kemp@otago.ac.nz

Competing Interests

GAL completed an MSc and was supported by Blis Technologies and Callaghan Innovation during her studies. This manuscript was prepared after submission of the thesis.

References

  1. Bull MJ, Plummer NT. Part 1: The human gut microbiome in health and disease. Integrative Medicine 2014; 13(6):17–22.
  2. Ozen M, Dinleyici EC. The history of probiotics: the untold story. Beneficial Microbes. 2015; 6(2):159–65.
  3. Ljungh A, Wadstrom T. Lactic acid bacteria as probiotics. Current Issues in Intestinal Microbiology. 2006; 7(2):73–89.
  4. Anderson RC, Cookson AL, McNabb WC, Park Z, McCann MJ, Kelly WJ, et al. Lactobacillus plantarum MB452 enhances the function of the intestinal barrier by increasing the expression levels of genes involved in tight junction formation. BMC Microbiology. 2010; 10(1):316.
  5. Todoriki K, Mukai T, Sato S, Toba T. Inhibition of adhesion of food-borne pathogens to Caco-2 cells by Lactobacillus strains. Journal of Applied Microbiology. 2001; 91(1):154–9.
  6. Sheu B-S, Cheng H-C, Kao A-W, Wang S-T, Yang Y-J, Yang H-B, et al. Pretreatment with Lactobacillus- and Bifidobacterium-containing yogurt can improve the efficacy of quadruple therapy in eradicating residual Helicobacter pylori infection after failed triple therapy. The American Journal of Clinical Nutrition. 2006; 83(4):864–9.
  7. Sartor RB. Mechanisms of Disease: pathogenesis of Crohn’s disease and ulcerative colitis. Nature Clinical Practice Gastroenterology & Hepatology. 2006; 3:390.
  8. Ashraf R, Shah NP. Immune system stimulation by probiotic microorganisms. Critical Reviews in Food Science and Nutrition. 2014; 54(7):938–56.
  9. Madsen KL, Doyle JS, Jewell LD, Tavernini MM, Fedorak RN. Lactobacillus species prevents colitis in interleukin 10 gene–deficient mice. Gastroenterology. 1999; 116(5):1107–14.
  10. Leyer GJ, Li S, Mubasher ME, Reifer C, Ouwehand AC. Probiotic effects on cold and influenza-like symptom incidence and duration in children. Pediatrics. 2009; 124(2):e172–e9.
  11. de Vrese M, Winkler P, Rautenberg P, Harder T, Noah C, Laue C, et al. Probiotic bacteria reduced duration and severity but not the incidence of common cold episodes in a double blind, randomized, controlled trial. Vaccine. 2006; 24(44):6670–4.
  12. Berggren A, Lazou Ahren I, Larsson N, Onning G. Randomised, double-blind and placebo-controlled study using new probiotic lactobacilli for strengthening the body immune defence against viral infections. European Journal of Nutrition. 2011; 50(3):203–10.
  13. Hammer GE, Turer EE, Taylor KE, Fang CJ, Advincula R, Oshima S, et al. Expression of A20 by dendritic cells preserves immune homeostasis and prevents colitis and spondyloarthritis. Nature Immunology. 2011; 12(12):1184–93.
  14. Takeda K, Suzuki T, Shimada S-I, Shida K, Nanno M, Okumura K. Interleukin-12 is involved in the enhancement of human natural killer cell activity by Lactobacillus casei Shirota. Clinical & Experimental Immunology. 2006; 146(1):109–15.
  15. Bourdeau T, Spertini F, Raymond F, Audran R, Gosoniu L, Mercenier A, et al. Transcriptomic analysis of PBMCs from allergic patients after probiotic treatment. Austin Journal of Nutrition and Metabolism. 2017; 4(1).
  16. Caballero-Franco C, Keller K, De Simone C, Chadee K. The VSL#3 probiotic formula induces mucin gene expression and secretion in colonic epithelial cells. American Journal of Physiology-Gastrointestinal and Liver Physiology. 2007; 292(1):G315–G22.
  17. Maneerat S, Lehtinen MJ, Childs CE, Forssten SD, Alhoniemi E, Tiphaine M, et al. Consumption of Bifidobacterium lactis Bi-07 by healthy elderly adults enhances phagocytic activity of monocytes and granulocytes. Journal of Nutritional Science. 2014; 2:e44.
  18. Ducrotté P, Sawant P, Jayanthi V. Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome. World Journal of Gastroenterology. 2012; 18(30):4012–8.
  19. Kechagia M, Basoulis D, Konstantopoulou S, Dimitriadi D, Gyftopoulou K, Skarmoutsou N, et al. Health benefits of probiotics: A Review. ISRN Nutrition. 2013; 2013:481651.
  20. Gurevitch J, Koricheva J, Nakagawa S, Stewart G. Meta-analysis and the science of research synthesis. Nature. 2018; 555:175.
  21. Preidis GA, Versalovic J. Targeting the human microbiome with antibiotics, probiotics, and prebiotics: gastroenterology enters the metagenomics era. Gastroenterology. 2009; 136(6):2015–31.
  22. Kandasamy S, Vlasova AN, Fischer DD, Chattha KS, Shao L, Kumar A, et al. Unraveling the differences between Gram-positive and Gram-negative probiotics in modulating protective immunity to enteric infections. Frontiers in Immunology. 2017; 8:334.
  23. Kelesidis T, Pothoulakis C. Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders. Therapeutic Advances in Gastroenterology. 2012; 5(2):111–25.
  24. Liévin-Le Moal V, Servin AL. Anti-infective activities of lactobacillus strains in the human intestinal microbiota: from probiotics to gastrointestinal anti-infectious biotherapeutic agents. Clinical Microbiology Reviews. 2014; 27(2):167–99.
  25. McFarland LV, Dublin S. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World Journal of Gastroenterology. 2008; 14(17):2650–61.
  26. Kristensen NB, Bryrup T, Allin KH, Nielsen T, Hansen TH, Pedersen O. Alterations in fecal microbiota composition by probiotic supplementation in healthy adults: a systematic review of randomized controlled trials. Genome Medicine. 2016; 8(1):52.
  27. Ivanov II, Honda K. Intestinal commensal microbes as immune modulators. Cell Host & Microbe. 2012; 12(4):496–508.
  28. Shane AL, Cabana MD, Vidry S, Merenstein D, Hummelen R, Ellis CL, et al. Guide to designing, conducting, publishing and communicating results of clinical studies involving probiotic applications in human participants. Gut Microbes. 2010; 1(4):243–53.
  29. Arora M, Baldi A. Regulatory categories of probiotics across the globe: A review representing existing and recommended categorization. Indian Journal of Medical Microbiology. 2015; 33(5):2–10.
  30. Venugopalan V, Shriner KA, Wong-Beringer A. Regulatory oversight and safety of probiotic use. Emerging Infectious Diseases. 2010; 16(11):1661–5.
  31. Katan MB. Health claims for functional foods: Regulations vary between countries and often permit vague claims. British Medical Journal. 2004; 328(7433):180–1.
  32. FSANZ. Notified food-health relationship to make a health claim: Food Standards Australia New Zealand; 2018 [Available from: http://www.foodstandards.govt.nz/industry/labelling/fhr/Pages/default.aspx
  33. Skokovic-Sunjic D. Clinical Guide to Probiotic Products Available in Canada: AEProbio; 2019 [Available from: http://www.probioticchart.ca

Download

The downloadable PDF version of this article is only available to subscribers.

To view this content please login or subscribe